Boehringer Ingelheim, a leader in animal health, has introduced VETMEDIN Solution, the first oral solution approved by the U.S. Food and Drug Administration (FDA) for managing congestive heart failure (CHF) in dogs caused by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM).
Heart disease is a significant issue for dogs, affecting about 10% of them during their lifetime. The most common conditions leading to CHF are MMVD and DCM, both of which can prevent the heart from effectively pumping blood.
VETMEDIN Solution offers pet owners a new, convenient option for treating CHF in dogs. This liquid formulation is designed for ease of administration, particularly for smaller dogs or those that may prefer liquid medication. Research has shown that VETMEDIN can enhance both the lifespan and quality of life for dogs suffering from these heart conditions.
Daniel Watkins, Vice President of U.S. Pet Business at Boehringer Ingelheim, stated, “We are committed to delivering new innovations based on strong clinical evidence to help more pets. We recognize that some dogs and their owners may prefer a liquid form of medication.
With VETMEDIN Solution, we can provide an easy-to-use option that may help more dogs with heart disease live longer, healthier lives.”
The new VETMEDIN Solution maintains the same dual-action mechanism as the existing VETMEDIN chewable tablets. It is a tasteless liquid that should be administered directly into the dog’s mouth twice daily.
Since its launch 25 years ago, VETMEDIN has contributed to over one million additional years of life for dogs worldwide.
The chewable tablets are approved for treating mild to severe CHF in dogs due to MMVD or DCM and can be used alongside other therapies as needed.
In addition to VETMEDIN Solution, Boehringer Ingelheim offers VETMEDIN-CA1 (pimobendan), which has FDA conditional approval for use in dogs with Stage B2 preclinical MMVD. This treatment may help delay the onset of heart failure symptoms.
Boehringer Ingelheim continues to innovate in the field of animal health, providing a range of vaccines, parasite control products, and medications for pets, horses, and livestock. As one of the top investors in research and development within the industry, the company focuses on creating innovative therapies to meet critical medical needs in both human and animal health.
Related topics:
- CARMAT Hosts Successful Inaugural “Aeson® European User Meeting”
- American Heart Association Launches Initiative to Teach Lifesaving CPR And AED Skills in Rural Alaska
- Eli Lilly’s Tirzepatide Shows Heart Benefits for Obese Patients with Heart Failure